Factbox-Global healthcare companies invest billions to boost US presence

Global healthcare companies are investing billions of dollars to strengthen their presence in the United States, anticipating changes to trade policies under the Trump administration. Major drugmakers such as Eli Lilly, Pfizer, AstraZeneca, and Roche have collectively committed over $500 billion in U.S. investments to bolster manufacturing and research operations.

Pfizer agreed to invest $70 billion in research and development and domestic manufacturing with President Trump last year, making it the cornerstone of their expansion strategy. Lilly, Pfizer, AstraZeneca, and Roche plan to collectively invest $55 billion over the next four years, aiming to mitigate supply-chain risks and enhance investor confidence.

The Swiss drugmaker Roche has pledged to increase its investment in U.S. manufacturing sites by nearly doubling its current $700 million commitment to about $2 billion, while AstraZeneca plans to spend over $1 billion in Massachusetts to grow its workforce by more than 50%. Sanofi, another key player, intends to invest $23 billion over five years to build and expand ten facilities in the U.S., including six new manufacturing plants and enhancing its San Diego research and development site.

These investments will create thousands of jobs and strengthen the U.S. presence of these global healthcare giants amidst potential tariff challenges.